<DOC>
	<DOC>NCT01933321</DOC>
	<brief_summary>Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.</brief_summary>
	<brief_title>Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
	<detailed_description>There is no more extensive information</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>patients with a confirmed diagnosis of ALS according to El Escorial criteria. Diagnosistime less than four years. Over 18 years old. Forced vital capacity â‰¥ 40%. One year of evolution. Adequate nutritional state Severe bulbar ALS involucre. Inadequate nutritional status. Spondylotic myelopathy, or abnormalities in imaging study. Having concomitant neurological or psychiatric disease. Systemic disease with poorcontrol. History of treatment with steroids or immunoglobulins in the last year. Participate in the past three months in a Clinical Trial. History of malignancy or cancer today. Intracranial hypertension. Clinical suggestive data of infection in the site of lumbar puncture. Tracheostomy. Use of mechanical ventilation. Forced vital capacity less than 40%. HIVseropositive or presence of antibodies against hepatitis B or C in the serological studies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>ALS, stem cells</keyword>
</DOC>